The IDCF programme is being implemented from 13th June to 27th June, 2022 in the states/UTs and the goal is to attain zero child deaths due to childhood diarrhoea
Next-generation booster vaccine candidate demonstrates potential to protect against COVID-19 variants of concern, including Omicron BA.1 and BA.2, with a favorable safety and tolerability profile
The production and supply in Canada are designed to address the growing need for no-carrier-added Lutetium-177 (n.c.a. Lu-177) in North America
Cantourage introduces second Clever Leaves medical cannabis product to the German market
Tislelizumab is now approved in nine indications in China
TAK-003 is currently undergoing regulatory review for potential licensure in both the European Union
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.
States have an important role in ensuring food safety and healthy food practices.
Based on a post hoc analysis, fewer required respiratory interventions
Subscribe To Our Newsletter & Stay Updated
